MyChart is not for medical emergencies. If you have a medical emergency, call 911.
If you need help with MyChart, call us at 1-844-442-4278
Prostate cancer is one of the most common and deadly cancers for American men. To better assist men at risk for the disease, we created the University of Chicago Medicine High-Risk and Advanced Prostate Cancer Clinic (UCHAP). The program provides a comprehensive genetic evaluation and multifaceted screening plan for men with an increased prostate cancer risk. If you’ve been recently diagnosed with aggressive forms of prostate cancer, our team also offers novel treatment strategies as well as access to leading-edge clinical trials.
Our team works with men who’ve been diagnosed with aggressive prostate cancer as well as those who have an elevated risk for developing prostate cancer in the future, typically due to genetic or inherited risk factors.
Prostate cancer risk factors:
Indications of aggressive or high-risk prostate cancer:
UChicago Medicine is a major center for conducting prostate cancer research through the National Cancer Institute and private sponsors. Additionally, UChicago Medicine sponsors many clinical trials that are designed by our own prostate cancer experts.
These clinical trials are testing novel surgical, radiation and medical treatments to fight prostate cancer and improve patients’ quality of life. Men who participate in prostate cancer research studies have a chance to benefit from treatments that have shown promise in previous research but are not yet widely available to the public.
If you’ve already been diagnosed with prostate cancer, you may be eligible to participate in a clinical trial to test new treatment strategies.
Our clinic includes a multidisciplinary team of specialists who provide high-quality screening and treatment strategies for men with prostate cancer, including:
Our expert team includes urologists, geneticists, medical oncologists, radiation oncologists, radiologists, pathologists, care navigators and research scientists who work together to provide the most advanced clinical care for men with prostate cancer.
Beyond our treatment strategies, we’re also committed to conducting comprehensive patient profiling and biobanking to advance scientific knowledge and ultimately improve prostate cancer treatment for men everywhere.
Hematology & Oncology (Cancer)
Hematology & Oncology (Cancer)
Sarah Nielsen, MS, CGC, is a licensed and board-certified genetic counselor in the Section of Hematology/Oncology at the University of Chicago Medicine. Nielsen received a bachelor of arts in biology from Lehigh University and a master’s of science in genetic counseling from the University of Pittsburgh. Her professional and research interests include genetic susceptibility to breast, ovarian and kidney cancers as well as endocrine tumor syndromes. She established the Endocrine Genetics Clinic and the Comprehensive von Hippel-Lindau disease (VHL) Clinical Care Center at the UChicago Medicine. Nielsen is also a member of the National Society of Genetic Counselors and a faculty member of the Northwestern University graduate program in genetic counseling, where she gives lectures and supervises students during their clinical rotations